Department of Biological Sciences, Center for Stem Cells and Regenerative Medicine, Center for Zebrafish Research, Boler-Parseghian Center for Rare and Neglected Diseases, Warren Center for Drug Discovery, University of Notre Dame, Notre Dame, IN 46556, USA.
Cells. 2023 May 18;12(10):1419. doi: 10.3390/cells12101419.
Endocannabinoid signaling plays crucial roles in human physiology in the function of multiple systems. The two cannabinoid receptors, CB1 and CB2, are cell membrane proteins that interact with both exogenous and endogenous bioactive lipid ligands, or endocannabinoids. Recent evidence has established that endocannabinoid signaling operates within the human kidney, as well as suggests the important role it plays in multiple renal pathologies. CB1, specifically, has been identified as the more prominent ECS receptor within the kidney, allowing us to place emphasis on this receptor. The activity of CB1 has been repeatedly shown to contribute to both diabetic and non-diabetic chronic kidney disease (CKD). Interestingly, recent reports of acute kidney injury (AKI) have been attributed to synthetic cannabinoid use. Therefore, the exploration of the ECS, its receptors, and its ligands can help provide better insight into new methods of treatment for a range of renal diseases. This review explores the endocannabinoid system, with a focus on its impacts within the healthy and diseased kidney.
内源性大麻素信号在人类生理学中多个系统的功能中起着至关重要的作用。两种大麻素受体，CB1 和 CB2，是细胞膜蛋白，与外源性和内源性生物活性脂质配体（或内源性大麻素）相互作用。最近的证据表明，内源性大麻素信号在人体肾脏中发挥作用，并表明它在多种肾脏病理中发挥着重要作用。具体来说，CB1 已被确定为肾脏中更为突出的 ECS 受体，这使我们能够将重点放在这个受体上。CB1 的活性已被反复证明有助于糖尿病和非糖尿病慢性肾脏病（CKD）。有趣的是，最近有报告称急性肾损伤（AKI）与合成大麻素的使用有关。因此，探索 ECS、其受体和配体可以帮助提供对一系列肾脏疾病新治疗方法的更好理解。本综述探讨了内源性大麻素系统，重点是其在健康和患病肾脏中的影响。
